These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27327285)

  • 1. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
    Baisiwala S; Bundorf MK; Pershing S
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
    Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
    JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
    Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open Payments Database: Anti-Vascular Endothelial Growth Factor Agent Payments to Ophthalmologists.
    Singh N; Chang JS; Rachitskaya AV
    Am J Ophthalmol; 2017 Jan; 173():91-97. PubMed ID: 27697472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration.
    Cheng S; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):458-65. PubMed ID: 27183550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study.
    Shah S; Markatia Z; Watane A; Feldman A; Shah L; Sridhar J
    Curr Opin Ophthalmol; 2023 May; 34(3):218-225. PubMed ID: 36866850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries.
    Thakore RV; Greenberg PB; Behrens JJ; French DD
    JAMA Ophthalmol; 2016 Sep; 134(9):1071-2. PubMed ID: 27366859
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept.
    Pershing S; Talwar N; Armenti ST; Grubbs J; Rosenthal JM; Dedania VS; Stein JD
    Am J Ophthalmol; 2019 Nov; 207():385-394. PubMed ID: 31100217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
    Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
    Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Analysis of Medicare Reimbursement to Ophthalmologists: Years 2012 to 2013.
    Han E; Baisiwala S; Jain A; Bundorf MK; Pershing S
    Am J Ophthalmol; 2017 Oct; 182():133-140. PubMed ID: 28784553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Anti-Vascular Endothelial Growth Factor Original Medicare Part B Claims in the United States, 2014-2019.
    Desai S; Sekimitsu S; Rossin EJ; Zebardast N
    Ophthalmic Epidemiol; 2024 Oct; 31(5):468-477. PubMed ID: 38315793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication.
    Williams PD; Chong D; Fuller T; Callanan D
    Retina; 2016 May; 36(5):909-13. PubMed ID: 27115856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between Industry Payments and Anti-vascular Endothelial Growth Factor Use in Medicare Beneficiaries.
    Mahr MA; Hodge DO; Erie JC
    Ophthalmol Retina; 2017; 1(1):19-24. PubMed ID: 31047391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
    Hall LB; Zebardast N; Huang JJ; Adelman RA
    J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
    Zhang C; Friedman S; Mruthyunjaya P; Parikh R
    Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.